Laquinimod presentations at ECTRIMS

(Thomson Reuters ONE) - Lund, Sweden, September 8, 2009 - Active Biotech AB's (NASDAQ OMXNordic: ACTI) collaboration partner Teva Pharmaceutical IndustriesLtd. (NASDAQ: TEVA) today announce information regarding the upcomingnovel data to be presented at ECTRIMS (25th Congress of the EuropeanCommittee for Treatment and Research in Multiple Sclerosis) inDüsseldorf, Germany September 9-12, 2009.To read the complete press release, please see www.tevapharm.com.For further information, please contact:Tomas Leanderson, President & CEOTel: +46 46 19 20 95E-mail: tomas.leanderson(at)activebiotech.comGöran Forsberg, VP Investor Relations & Business DevelopmentTel: +46 (0) 46 19 11 54E-mail: goran.forsberg(at)activebiotech.comAbout Active BiotechActive Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnologycompany with focus on autoimmune/inflammatory diseases and cancer.Projects in pivotal phase are laquinimod, an orally administeredsmall molecule with unique immunomodulatory properties for thetreatment of multiple sclerosis, as well as ANYARA for use in cancertargeted therapy, primarily of renal cancer. Further key projects inclinical development comprise the three orally administered compoundsTASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Pleasevisit www.activebiotech.com for more information.Active Biotech ABPO Box 724, SE-220 07 LundSwedenTel: +46 (0)46-19 20 00Fax: +46 (0)46-19 11 00Active Biotech is required under the Securities Markets Act to makethe information in this press release public. The information wassubmitted for publication at 4:15 p.m. CET on September 8, 2009.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 08.09.2009 - 16:16 Uhr
Sprache: Deutsch
News-ID 5600
Anzahl Zeichen: 0

contact information:
Town:

London

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 335 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Laquinimod presentations at ECTRIMS"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech